STING1 and Aicardi-Goutieres syndrome: Unlike agonists, STING inhibitors are being developed to mitigate unwanted STING activation, which is associated with chronic inflammatory diseases like lupus, Aicardi–Goutières syndrome, myocardial infarction, and other interferonopathies (Zhang et al., 2022).